Recombinant Human ITIH1 His-tag Protein, CF

When Recombinant Human ITIH1 (Catalog # 10268-IT) is coated at 2 μg/mL, 100 μL/well, Recombinant Human TSG‑6 (Catalog # 2104-TS) binds with an ED50 of 1‑6 μg/mL.

2 μg/lane of Recombinant Human ITIH1 His-tag was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing a band at 80 kDa under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ITIH1 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human ITIH1 is immobilized at 2 μg/mL (100 μL/well), the concentration of Recombinant Human TSG‑6 (Catalog # 2104-TS) that produces 50% of the optimal binding response is 1-6 μg/mL
• Source: Chinese Hamster Ovary cell line, CHO-derived human ITIH1 protein
  Ser30-Asp672, with a C-terminal 6-His tag
• Accession #: P19827-1
• N-terminal Sequence: Ser30
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 73 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 79-82 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ITIH1 His-tag Protein, CF

• H1P
• IATIH
• IGHEP1
• inter-alpha (globulin) inhibitor H1
• inter-alpha (globulin) inhibitor, H1 polypeptide
• Inter-alpha-inhibitor heavy chain 1
• Inter-alpha-trypsin inhibitor complex component III
• inter-alpha-trypsin inhibitor heavy chain H1
• ITI heavy chain H1
• ITIH
• ITIH1
• ITI-HC1
• MGC126415
• Serum-derived hyaluronan-associated protein
• SHAP

Background

Inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1) is a heavy chain (HC) member of the ITIH family that is synthesized in the liver and circulates in the plasma (1). ITIH1 contains a signal sequence, propeptide, and a conserved von-Willebrand type A domain as in other HCs in the family. ITIH1 also includes a c-terminal extension multicopper oxidase domain, present in ITIH3 as well, that is trimmed to reveal a c-terminal aspartic acid residue that enables crosslinking of the HC to chondroitin sulfate (CS) (1,2). ITIH1 represents the HC1 component of Inter-alpha -inhibitor.  Inter-alpha -inhibitor is a protease inhibitor composed of three subunits (HC1, HC2, and bikunin), which are linked together via a CS moiety (1,3). ITIH1 can alternatively be associated with hyaluronan (HA) to form the Serum-derived hyaluronan associated protein (SHAP)-hyaluronan (HA) complex known to assist in stabilizing HA-rich extracellular matrices in the context of inflammatory processes and ovulation (3,4).  Tumor necrosis factor-stimulated gene-6 (TSG-6) has high affinity for heavy chains and plays an important role in the transfer of HC to HA matrix by forming a TSG-6:HC complex intermediate required for the transfer (4,5). Inter-alpha -inhibitor heavy chains potentiate CD-44-mediated leukocytes adhesion to hyaluronan substratum and recruit immune cells to sites of inflammation (6).  The SHAP-HA complex was found to be upregulated in patients at various clinical stages of chronic hepatitis (CH), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) caused by infection with the hepatitis C or hepatitis B virus (7).  ITIH1 has been shown to increase cell attachment and reduce the number of metastases in an antitumoral role (8).

1. Salier, J.P. et al. (1996) Biochem. J. 315:1.
2. Jean, L. et al. (1997) Genomics 41:139.
3. Zhuo, L. et al. (2004) J. Biol. Chem. 279:38079.
4. Rugg, M.S. et al. (2005) J. Biol. Chem. 280:25674.
5. Baranova, N.S et al. (2013) J. Biol. Chem. 288: 29642.
6. Zhuo, L. et al. (2006) J. Biol. Chem. 281:20303.
7. Shen, L. et al.  (2006) Hepatol. Res. 34:178.
8. Paris, S. et al. (2002) Int. J. Cancer 97:615.

Bioinformatics

• Uniprot:
  • P19827-1()